Seysara Shortage Update: What Patients Need to Know in 2026

If you've been searching for Seysara (sarecycline) at pharmacies near you and keep coming up empty, you may be wondering whether there's an official shortage. Here's an honest, up-to-date breakdown of where Seysara availability stands in 2026 and what you should know as a patient trying to manage your acne treatment.

Is Seysara Officially in Shortage in 2026?

As of 2026, Seysara (sarecycline) is not listed on the FDA's Drug Shortage Database. This means there is no manufacturer-declared, FDA-confirmed shortage of Seysara at the national level.

However, this doesn't mean Seysara is easy to find. The FDA shortage list captures systemic supply failures — it doesn't reflect the many ways a drug can be locally unavailable. Seysara's challenges are structural rather than a supply chain emergency.

Why Seysara Is Hard to Find Even Without a Formal Shortage

Seysara is a brand-name-only drug — no generic version exists as of 2026. Its retail cash price exceeds $1,100 per month, and many insurance plans either don't cover it or require prior authorization. These factors combine to create a market where:

Prescription volume is relatively low compared to generic alternatives like doxycycline

Many pharmacies don't routinely stock it, especially in areas without nearby dermatology practices

Patients who are prescribed Seysara often must search multiple pharmacies to fill their prescription

The three-strength dosing system (60 mg, 100 mg, 150 mg) means pharmacies must stock multiple SKUs for a drug with modest demand

Background: Seysara's Availability History

Seysara was FDA-approved in October 2018 and brought to market by Allergan, which was later acquired by Almirall. The drug was the first new oral antibiotic for acne in over 40 years, and it generated significant interest in dermatology circles.

Since launch, Seysara has maintained a niche position in the acne treatment landscape. It's positioned as a premium option over older tetracyclines, but its high price point has created a divide between clinical enthusiasm and patient access. The American Academy of Dermatology conditionally recommends Seysara for acne — acknowledging its clinical benefits while noting that cost concerns may affect access.

What the "Shortage" Experience Feels Like for Patients

Even without a formal FDA shortage, many Seysara patients describe an experience that feels like a shortage: calling multiple pharmacies, being told the drug isn't in stock, waiting days for pharmacies to order it, or finding that only one pharmacy in a 20-mile radius carries their dose strength.

This is a real and frustrating problem even if it doesn't meet the technical threshold for an FDA shortage declaration.

What Can Patients Do Right Now?

The most efficient step you can take is to use medfinder, a paid service that calls pharmacies near you to check which ones have Seysara in stock. Rather than calling pharmacies yourself — often with long hold times and inconsistent answers — medfinder handles the outreach and texts you the results.

Additional steps you can take:

Ask your dermatologist to send your prescription to a pharmacy they know carries Seysara

Request home delivery through a specialty pharmacy

Explore the Almirall Advantage savings program to access Seysara through preferred pharmacies at reduced cost

If Seysara remains consistently unavailable, discuss alternative acne antibiotics with your dermatologist

Will Seysara Get Easier to Find?

Seysara's availability is likely to improve if and when a generic version becomes available — which would dramatically lower the price and increase demand. Until then, availability will depend primarily on insurance formulary decisions and whether more insurance plans add Seysara coverage without requiring onerous prior authorization.

For now, the most practical solution remains proactive searching — starting your refill search a week early, building a relationship with a pharmacy that stocks it, and having a backup plan in place if it's temporarily unavailable.